Share Price and Basic Stock Data
Last Updated: February 13, 2026, 9:02 pm
| PEG Ratio | -5.83 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MK Proteins Ltd operates in the edible oils and solvent extraction industry, with a current market capitalization of ₹203 Cr and a share price of ₹5.43. The company’s revenue has shown variability over the years, with sales recorded at ₹315 Cr for the year ending March 2023, declining to ₹245 Cr in March 2024, and subsequently increasing to ₹268 Cr for March 2025. Quarterly sales figures have also fluctuated, with the latest reported sales of ₹86.87 Cr in March 2024, which saw a decline to ₹57.33 Cr in June 2024. The company’s historical sales peaked at ₹311 Cr in March 2021 but has since faced challenges, as evidenced by the decline in annual sales from ₹256 Cr in March 2022 to ₹245 Cr in March 2024. The recent sales growth in the trailing twelve months (TTM) stands at ₹324 Cr, indicating a potential recovery trend. However, the inconsistency in revenue generation raises concerns about market stability and operational efficiency.
Profitability and Efficiency Metrics
Profitability metrics for MK Proteins Ltd reveal a mixed performance. The operating profit margin (OPM) stood at 3.21%, reflecting low profitability compared to industry norms. The company reported a net profit of ₹8 Cr for the fiscal year ending March 2025, translating to an earnings per share (EPS) of ₹0.22. The net profit margin decreased to 3.13% in March 2025 from 4.56% in March 2024, indicating a decline in profitability. The interest coverage ratio (ICR) was robust at 11.68x, suggesting ample ability to cover interest payments, which is favorable compared to sector standards. The cash conversion cycle (CCC) extended to 142 days, indicating potential inefficiencies in inventory management and receivables collection. While the return on equity (ROE) at 12.4% demonstrates a reasonable return to shareholders, the overall profitability metrics highlight areas needing improvement to align with sector averages.
Balance Sheet Strength and Financial Ratios
The balance sheet of MK Proteins Ltd reflects a conservative capital structure, with total borrowings standing at ₹2 Cr against reserves of ₹36 Cr. The debt-to-equity ratio is notably low at 0.54, indicating prudent financial management and a low reliance on debt financing. The company’s total assets increased to ₹131 Cr in March 2025, up from ₹96 Cr in March 2024, supported by a consistent growth in reserves. The current ratio, reported at 2.01, suggests strong short-term liquidity, which is favorable compared to typical industry benchmarks. However, the price-to-book value (P/BV) ratio was recorded at 3.26x, indicating that the market has a high valuation on the company relative to its book value, which might imply investor confidence but also raises concerns about overvaluation. The return on capital employed (ROCE) stood at 12.9%, indicating effective use of capital, although it has seen a decline from previous years.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MK Proteins Ltd indicates a strong promoter holding of 74.82%, which has remained stable over recent quarters. The absence of foreign institutional investors (FIIs) and a public holding of 25.17% highlight a lack of external market participation. The number of shareholders has significantly increased from 87 in September 2022 to 72,294 by September 2025, indicating growing retail investor interest. However, the stability in promoter holding may limit the potential for new strategic investments or partnerships. The recent increase in public shareholders suggests that retail interest is on the rise, which could bolster market confidence. Despite the strong promoter backing, the lack of institutional investment may signal caution among larger investors regarding the company’s growth prospects and operational challenges.
Outlook, Risks, and Final Insight
Looking ahead, MK Proteins Ltd faces both opportunities and challenges. The recent uptick in TTM sales suggests a recovery, but profitability remains a concern given the declining net profit margins and operational inefficiencies reflected in the high cash conversion cycle. Risks include the volatility in raw material prices, which can significantly impact margins, and the company’s reliance on domestic markets, exposing it to regional economic fluctuations. Additionally, the absence of institutional investors may limit access to capital for expansion. However, if the company can streamline operations and enhance its profitability metrics, it may attract more institutional interest and stabilize its revenue streams. The focus on improving efficiency and managing costs will be crucial for sustaining growth and enhancing shareholder value in the competitive edible oils sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 462 Cr. | 348 | 610/298 | 12.7 | 107 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 90.1 Cr. | 6.91 | 10.3/4.00 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 302 Cr. | 1.61 | 3.15/1.50 | 211 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 60.8 Cr. | 2.55 | 3.95/1.45 | 23.7 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 3,646 Cr. | 1,303 | 3,633/321 | 1,796 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 10,214.14 Cr | 165.75 | 141.14 | 37.26 | 0.18% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Mar 2017 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53.59 | 76.20 | 13.64 | 68.86 | 86.87 | 57.33 | 33.69 | 39.48 | 137.20 | 114.95 | 32.43 |
| Expenses | 51.69 | 72.21 | 13.00 | 65.30 | 78.44 | 53.59 | 31.46 | 37.69 | 132.55 | 109.44 | 31.39 |
| Operating Profit | 1.90 | 3.99 | 0.64 | 3.56 | 8.43 | 3.74 | 2.23 | 1.79 | 4.65 | 5.51 | 1.04 |
| OPM % | 3.55% | 5.24% | 4.69% | 5.17% | 9.70% | 6.52% | 6.62% | 4.53% | 3.39% | 4.79% | 3.21% |
| Other Income | 0.01 | 0.00 | 0.03 | 0.01 | 0.41 | 0.00 | 0.21 | 0.25 | 0.02 | 0.00 | 0.12 |
| Interest | 0.69 | 0.52 | 0.04 | 0.11 | 0.40 | 0.33 | 0.03 | 0.07 | 0.67 | 0.70 | 0.06 |
| Depreciation | 0.30 | 0.12 | 0.12 | 0.12 | 0.18 | 0.07 | 0.07 | 0.11 | 0.09 | 0.10 | 0.11 |
| Profit before tax | 0.92 | 3.35 | 0.51 | 3.34 | 8.26 | 3.34 | 2.34 | 1.86 | 3.91 | 4.71 | 0.99 |
| Tax % | 36.96% | 25.67% | 21.57% | 25.75% | 29.42% | 25.45% | 25.21% | 25.81% | 28.64% | 25.27% | 25.25% |
| Net Profit | 0.57 | 2.49 | 0.41 | 2.48 | 5.83 | 2.48 | 1.74 | 1.38 | 2.80 | 3.51 | 0.75 |
| EPS in Rs | 0.02 | 0.07 | 0.01 | 0.07 | 0.16 | 0.07 | 0.05 | 0.04 | 0.07 | 0.09 | 0.02 |
Last Updated: January 11, 2026, 2:17 pm
Below is a detailed analysis of the quarterly data for MK Proteins Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 32.43 Cr.. The value appears to be declining and may need further review. It has decreased from 114.95 Cr. (Jun 2025) to 32.43 Cr., marking a decrease of 82.52 Cr..
- For Expenses, as of Sep 2025, the value is 31.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 109.44 Cr. (Jun 2025) to 31.39 Cr., marking a decrease of 78.05 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.04 Cr.. The value appears to be declining and may need further review. It has decreased from 5.51 Cr. (Jun 2025) to 1.04 Cr., marking a decrease of 4.47 Cr..
- For OPM %, as of Sep 2025, the value is 3.21%. The value appears to be declining and may need further review. It has decreased from 4.79% (Jun 2025) to 3.21%, marking a decrease of 1.58%.
- For Other Income, as of Sep 2025, the value is 0.12 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.12 Cr., marking an increase of 0.12 Cr..
- For Interest, as of Sep 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.70 Cr. (Jun 2025) to 0.06 Cr., marking a decrease of 0.64 Cr..
- For Depreciation, as of Sep 2025, the value is 0.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.10 Cr. (Jun 2025) to 0.11 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.99 Cr.. The value appears to be declining and may need further review. It has decreased from 4.71 Cr. (Jun 2025) to 0.99 Cr., marking a decrease of 3.72 Cr..
- For Tax %, as of Sep 2025, the value is 25.25%. The value appears to be improving (decreasing) as expected. It has decreased from 25.27% (Jun 2025) to 25.25%, marking a decrease of 0.02%.
- For Net Profit, as of Sep 2025, the value is 0.75 Cr.. The value appears to be declining and may need further review. It has decreased from 3.51 Cr. (Jun 2025) to 0.75 Cr., marking a decrease of 2.76 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.09 (Jun 2025) to 0.02, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 122 | 123 | 145 | 165 | 172 | 157 | 194 | 311 | 256 | 315 | 245 | 268 | 324 |
| Expenses | 119 | 119 | 141 | 160 | 166 | 152 | 189 | 295 | 240 | 298 | 229 | 255 | 311 |
| Operating Profit | 3 | 4 | 4 | 5 | 6 | 5 | 5 | 16 | 16 | 17 | 17 | 13 | 13 |
| OPM % | 2% | 3% | 3% | 3% | 3% | 3% | 2% | 5% | 6% | 5% | 7% | 5% | 4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 2 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 14 | 14 | 15 | 15 | 11 | 11 |
| Tax % | 33% | 32% | 31% | 35% | 35% | 28% | 26% | 27% | 27% | 27% | 28% | 27% | |
| Net Profit | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 11 | 8 | 8 |
| EPS in Rs | 0.82 | 1.40 | 1.20 | 0.04 | 0.04 | 0.04 | 0.05 | 0.28 | 0.27 | 0.29 | 0.30 | 0.22 | 0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 400.00% | 0.00% | 10.00% | 0.00% | -27.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | -100.00% | 400.00% | -400.00% | 10.00% | -10.00% | -27.27% |
MK Proteins Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 2% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | -7% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 39% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 10:00 am
Balance Sheet
Last Updated: December 10, 2025, 3:01 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.68 | 0.68 | 0.68 | 3 | 4 | 4 | 4 | 4 | 4 | 13 | 38 | 38 | 38 |
| Reserves | 1 | 2 | 3 | 2 | 11 | 13 | 15 | 25 | 35 | 37 | 24 | 32 | 36 |
| Borrowings | 28 | 20 | 26 | 31 | 33 | 26 | 31 | 25 | 37 | 46 | 20 | 39 | 2 |
| Other Liabilities | 2 | 13 | 10 | 12 | 8 | 4 | 7 | 13 | 10 | 8 | 15 | 22 | 4 |
| Total Liabilities | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 80 |
| Fixed Assets | 3 | 6 | 7 | 7 | 6 | 4 | 3 | 2 | 3 | 3 | 3 | 4 | 3 |
| CWIP | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Other Assets | 26 | 29 | 32 | 40 | 50 | 43 | 53 | 65 | 83 | 100 | 88 | 120 | 66 |
| Total Assets | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 80 |
Below is a detailed analysis of the balance sheet data for MK Proteins Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 38.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 38.00 Cr..
- For Reserves, as of Sep 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 4.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 37.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). It has decreased from 22.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 18.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 80.00 Cr.. The value appears to be improving (decreasing). It has decreased from 131.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 51.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Investments, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Sep 2025, the value is 66.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 54.00 Cr..
- For Total Assets, as of Sep 2025, the value is 80.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 51.00 Cr..
Notably, the Reserves (36.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -16.00 | -22.00 | -26.00 | -27.00 | -21.00 | -26.00 | -9.00 | -21.00 | -29.00 | -3.00 | -26.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 16 | 27 | 10 | 39 | 25 | 18 | 24 | 42 | 19 | 5 | 2 |
| Inventory Days | 62 | 70 | 57 | 83 | 69 | 75 | 79 | 48 | 80 | 91 | 134 | 170 |
| Days Payable | 6 | 39 | 22 | 23 | 12 | 6 | 8 | 10 | 8 | 6 | 19 | 29 |
| Cash Conversion Cycle | 75 | 47 | 62 | 70 | 97 | 94 | 89 | 62 | 114 | 104 | 120 | 142 |
| Working Capital Days | 69 | 11 | 9 | 20 | 44 | 32 | 36 | 36 | 55 | 57 | 77 | 81 |
| ROCE % | 10% | 14% | 13% | 12% | 11% | 8% | 8% | 29% | 23% | 20% | 19% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Diluted EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Cash EPS (Rs.) | 0.23 | 0.31 | 9.11 | 26.61 | 27.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Revenue From Operations / Share (Rs.) | 7.13 | 6.54 | 251.64 | 613.52 | 745.89 |
| PBDIT / Share (Rs.) | 0.34 | 0.45 | 13.66 | 37.85 | 38.31 |
| PBIT / Share (Rs.) | 0.33 | 0.44 | 13.06 | 35.66 | 36.13 |
| PBT / Share (Rs.) | 0.30 | 0.41 | 11.67 | 33.67 | 34.34 |
| Net Profit / Share (Rs.) | 0.22 | 0.29 | 8.51 | 24.42 | 24.91 |
| PBDIT Margin (%) | 4.82 | 6.94 | 5.42 | 6.16 | 5.13 |
| PBIT Margin (%) | 4.69 | 6.73 | 5.18 | 5.81 | 4.84 |
| PBT Margin (%) | 4.27 | 6.29 | 4.63 | 5.48 | 4.60 |
| Net Profit Margin (%) | 3.13 | 4.56 | 3.38 | 3.98 | 3.33 |
| Return on Networth / Equity (%) | 12.08 | 18.35 | 21.17 | 25.71 | 35.41 |
| Return on Capital Employeed (%) | 17.54 | 26.54 | 30.87 | 35.13 | 44.53 |
| Return On Assets (%) | 6.43 | 11.64 | 10.14 | 11.82 | 15.42 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.05 | 0.06 | 0.15 |
| Total Debt / Equity (X) | 0.54 | 0.31 | 0.88 | 0.92 | 0.83 |
| Asset Turnover Ratio (%) | 2.36 | 2.44 | 3.30 | 3.33 | 5.02 |
| Current Ratio (X) | 2.01 | 2.53 | 1.96 | 1.88 | 1.92 |
| Quick Ratio (X) | 0.12 | 0.19 | 0.58 | 0.74 | 0.79 |
| Inventory Turnover Ratio (X) | 2.81 | 2.73 | 4.23 | 4.49 | 5.77 |
| Interest Coverage Ratio (X) | 11.68 | 16.02 | 9.86 | 18.96 | 21.31 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 11.53 | 7.14 | 13.23 | 14.86 |
| Enterprise Value (Cr.) | 264.44 | 389.87 | 957.87 | 116.65 | 57.72 |
| EV / Net Operating Revenue (X) | 0.98 | 1.59 | 3.04 | 0.45 | 0.18 |
| EV / EBITDA (X) | 20.49 | 22.85 | 56.03 | 7.39 | 3.61 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| Price / BV (X) | 3.26 | 6.07 | 18.17 | 2.02 | 1.13 |
| Price / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| EarningsYield | 0.03 | 0.03 | 0.01 | 0.12 | 0.31 |
After reviewing the key financial ratios for MK Proteins Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 3. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.13. It has increased from 6.54 (Mar 24) to 7.13, marking an increase of 0.59.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.34, marking a decrease of 0.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.33, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.41 (Mar 24) to 0.30, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 2. It has decreased from 0.29 (Mar 24) to 0.22, marking a decrease of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 10. It has decreased from 6.94 (Mar 24) to 4.82, marking a decrease of 2.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 10. It has decreased from 6.73 (Mar 24) to 4.69, marking a decrease of 2.04.
- For PBT Margin (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 10. It has decreased from 6.29 (Mar 24) to 4.27, marking a decrease of 2.02.
- For Net Profit Margin (%), as of Mar 25, the value is 3.13. This value is below the healthy minimum of 5. It has decreased from 4.56 (Mar 24) to 3.13, marking a decrease of 1.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.08. This value is below the healthy minimum of 15. It has decreased from 18.35 (Mar 24) to 12.08, marking a decrease of 6.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.54. This value is within the healthy range. It has decreased from 26.54 (Mar 24) to 17.54, marking a decrease of 9.00.
- For Return On Assets (%), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.64 (Mar 24) to 6.43, marking a decrease of 5.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.54, marking an increase of 0.23.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.36. It has decreased from 2.44 (Mar 24) to 2.36, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.53 (Mar 24) to 2.01, marking a decrease of 0.52.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.12, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 2.81, marking an increase of 0.08.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.68. This value is within the healthy range. It has decreased from 16.02 (Mar 24) to 11.68, marking a decrease of 4.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 11.53 (Mar 24) to 8.60, marking a decrease of 2.93.
- For Enterprise Value (Cr.), as of Mar 25, the value is 264.44. It has decreased from 389.87 (Mar 24) to 264.44, marking a decrease of 125.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 1.59 (Mar 24) to 0.98, marking a decrease of 0.61.
- For EV / EBITDA (X), as of Mar 25, the value is 20.49. This value exceeds the healthy maximum of 15. It has decreased from 22.85 (Mar 24) to 20.49, marking a decrease of 2.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For Price / BV (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has decreased from 6.07 (Mar 24) to 3.26, marking a decrease of 2.81.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MK Proteins Ltd:
- Net Profit Margin: 3.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.54% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.08% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.4 (Industry average Stock P/E: 141.14)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Naraingarh Road, Village Garnala, Ambala District Haryana 134003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Parvind Kumar | Chairman |
| Mr. Parmod Kumar | Managing Director |
| Mr. Vinod Kumar | Whole Time Director |
| Ms. Laxmi Mandal | Independent Director |
| Mr. Tej Mohan Singh | Independent Director |
| Mrs. Shipra Jain | Independent Director |
| Mr. Raj Kumar | Non Executive Director |
FAQ
What is the intrinsic value of MK Proteins Ltd?
MK Proteins Ltd's intrinsic value (as of 13 February 2026) is ₹4.45 which is 15.40% lower the current market price of ₹5.26, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹197 Cr. market cap, FY2025-2026 high/low of ₹9.78/4.51, reserves of ₹36 Cr, and liabilities of ₹80 Cr.
What is the Market Cap of MK Proteins Ltd?
The Market Cap of MK Proteins Ltd is 197 Cr..
What is the current Stock Price of MK Proteins Ltd as on 13 February 2026?
The current stock price of MK Proteins Ltd as on 13 February 2026 is ₹5.26.
What is the High / Low of MK Proteins Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MK Proteins Ltd stocks is ₹9.78/4.51.
What is the Stock P/E of MK Proteins Ltd?
The Stock P/E of MK Proteins Ltd is 23.4.
What is the Book Value of MK Proteins Ltd?
The Book Value of MK Proteins Ltd is 1.96.
What is the Dividend Yield of MK Proteins Ltd?
The Dividend Yield of MK Proteins Ltd is 0.00 %.
What is the ROCE of MK Proteins Ltd?
The ROCE of MK Proteins Ltd is 12.9 %.
What is the ROE of MK Proteins Ltd?
The ROE of MK Proteins Ltd is 12.4 %.
What is the Face Value of MK Proteins Ltd?
The Face Value of MK Proteins Ltd is 1.00.